Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen

International Journal of Biological Markers

Volumn 13, Issue 1, 1998, Pages 30-41

  Dittadi, R ^a   Biganzoli, E ^b   Boracchi, P ^c   Salbe, C ^a   Mione, R ^a   Gatti, C ^a   Gion, M ^a  

^a Ospedale Civile Dolo   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer cathepsin D; Continuous variables; pS2; Steroid receptors

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN PS2; STEROID RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CYTOSOL; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROGNOSIS; PROTEIN INTERACTION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0031819577     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089801300106     Document Type: Article

References (37)

1. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line. Nucleic Acid Res 1982; 10: 7895-903.
2. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 1980; 20: 352-6.
3. Manning DL, McClelland RA, Gee JMW, et al. The role of four estrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer 1993; 29A: 1462-8.
4. Thorpe SM. Estrogen and progesterone receptor determination in breast cancer. Technology biology and clinical significance. Acta Oncol 1988; 27: 1-9.
5. Foekens JA, Van Putten WLJ, Portengen H, et al. Prognostic value of pS2 and cathepsin D in 710 human primary breast tumours: multivariate analysis. J Clin Oncol 1993; 11: 899-908.
6. Spyratos F, Andrieu C, Hacène K, Chambon P, Rio MC. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994; 69: 394-7.
7. Westley BR, May FEB. Cathepsin D and breast cancer. Eur J Cancer 1996; 32A: 15-24.
8. Manning DL, McClelland RA, Knowlden JM, et al. Differential expression of estrogen regulated genes in breast cancer. Acta Oncologica 1995; 34: 641-6.
9. Roberts M, Wallace J, Jeltsch JM, Berry M. The 5' flanking region of the human pS2 gene mediates its transcriptional activation by estrogen in MCF-7 cells. Biochem Biophys Res Comm 1988; 151: 306-13.
10. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987; 51: 941-51.
11. Cavailles V, Angerean P, Rochefort H. Cathepsin D is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. Proc Natl Acad Sci USA 1993; 90: 203-7.
12. Chalbos D, Philips A, Galteir F, Rochefort H. Synthetic antiestrogens modulate induction of pS2 and cathepsin D messenger ribonucleic acid by growth factors and adenosine 3'5' monophosphate in MCF-7 cells. Endocrinol 1993; 133: 571-6.
13. Nunez AM, Berry M, Imler JL, Chambon P. The 5' flanking region of pS2 gene contains a complex enhancer region responsive to estrogens, epidermal growth factor, a tumor promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. The EMBO J 1989; 8: 823-9.
14. Cavailles V, Augerau P, Garcia M, Rochefort H. Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin D secreted by breast cancer cells. Nucl Acids Res 1988; 16: 1903-19.
15. Maudelonde T, Escot C, Pujol P, et al. In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer. Eur J Cancer 1994; 30A: 2049-53.
16. Rajah TT, Dunn ST, Pento JT. The influence of antiestrogens on pS2 and cathepsin D mRNA. Induction in MCF-7 breast cancer cells. Anticancer Res 1996; 16: 837-42.
17. Toitou I, Vignon F, Cavailles V, Rochefort H. Hormonal regulation of cathepsin D following transfection of the estrogen or progesterone receptor into three sex steroid hormone resistant cancer cell lines. J Steroid Biochem Molec Biol 1991; 40: 231-7.
18. Clark GM, Wenger CR, Beardslee S, et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 1993; 71: 2157-62.
19. Mangasarian OL, Street WN, Wolberg WH. Breast cancer diagnosis and prognosis via linear programming. Operations Res 1995; 43: 570-7.
20. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995; 72: 511-8.
21. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Danger of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-35.
22. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC Workshop. Eur J Cancer 1980; 16: 1513-5.
23. Gion M, Mione R, Dittadi R, et al. Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 1995; 31A: 671-7.
24. Gion M, Mione R, Pappagallo GL, et al. pS2 in breast cancer - alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 1993; 68: 374-9.
25. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. John Wiley & Sons eds, Chichester 1995.
26. Therneau TM, Grambsch PM, Flemming TR. Martingale-based residuals for survival models. Biometrika 1990; 77: 147-60.
27. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8: 551-61.
28. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Patrov BN, Csaki F, eds. Proceedings of the Second International Symposium on Information Theory. Budapest: Akademia Kiado 1973.
29. Harrell FE Jr, Lee KL, Mark DB. Tutorial in biostatistics multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
30. Cazin J-L, Gosselin P, Boniface B, Boniface M, Demaille A. Expression of pS2 and cathepsin D in breast cancer. Int J Oncol 1993; 2: 1081-4.
31. Bolufer P, Torregrosa MD, Gomez L, et al. Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, oestradiol receptors, epidermal growth factor receptor and neu amplification. Clin Chim Acta 1996; 247: 89-103.
32. Soubeyran I, Quénel N, Mauriac L, Durand M, Bonichon F, Coindre J-M. Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases. Br J Cancer 1996; 73: 735-43.
33. Wesdey B, May FEB, Brown AMC, et al. Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52 and 160 kilodalton proteins in MCF-7 cells and two tamoxifen resistant sublines. J Biol Chem 1984; 259: 10030-5.
34. Waseda N, Kato Y, Imura H, Kurata M. Effects of ta moxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res 1981; 41: 1984-8.
35. Fernö M, Baldetorp B, Borg Å, et al. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 1994; 30A: 2042-8.
36. Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994; 30: 117-26.
37. Galea MH, Blarney RW, Elston CW, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-19.